替加环素
淋病奈瑟菌
微生物学
体内
抗生素
头孢曲松
抗菌剂
重新调整用途
最小抑制浓度
奈瑟菌科
生物
医学
鲍曼不动杆菌
抗菌剂
药理学
最低杀菌浓度
体外
杀菌剂
性传播疾病
作者
Xia Sun,Wenyan Lu,Haoyu Ge,Yuling Qin,Dailin Yuan,Xu’ai Lin,Yuefeng Rao,Stijn van der Veen
摘要
OBJECTIVES: The global emergence of ceftriaxone-resistant Neisseria gonorrhoeae threatens current first-line treatment and necessitates alternative therapeutic options. Tigecycline, a last-line glycylcycline antibiotic approved for complicated infections, was evaluated for repurposing against N. gonorrhoeae through in vitro and in vivo activity studies. METHODS: Antimicrobial susceptibility testing was performed for 616 clinical isolates (2011-2024) from Hangzhou, China, and bactericidal activity was determined in time-kill assays. A mouse vaginal tract infection model was used to evaluate in vivo tigecycline activity. Chequerboard assays were performed to assess interactions between tigecycline and ceftriaxone. RESULTS: Tigecycline demonstrated potent activity (MIC50: 0.125 mg/L; MIC90: 0.25 mg/L), including against tetracycline-resistant (tetracycline MIC50: 2 mg/L; MIC90: 64 mg/L) and high-level ceftriaxone-resistant (ceftriaxone MIC50: 0.03 mg/L; MIC90: 0.125 mg/L) strains. Time-kill assays (2 strains) revealed concentration-dependent bactericidal activity, with 4×MIC achieving ≥105-fold killing. In the mouse vaginal tract infection model, high-dose tigecycline (25 mg/kg) significantly enhanced bacterial clearance, eliminating infection within 3-6 days compared to 8-12 days in vehicle controls, and substantially reduced bacterial burden. Chequerboard assays against 21 isolates (10 ceftriaxone-susceptible, 11 ceftriaxone-resistant) demonstrated indifferent interactions between tigecycline and ceftriaxone (fractional inhibitory concentration indices 1.03-2.56), indicating no antagonism. CONCLUSIONS: These findings establish that tigecycline exhibits potent, rapid bactericidal activity against N. gonorrhoeae, including against high-level ceftriaxone-resistant strains, with robust in vivo efficacy. They support further investigation of tigecycline as a potential repurposing candidate for multidrug-resistant gonorrhoea, although its clinical role remains to be defined.
科研通智能强力驱动
Strongly Powered by AbleSci AI